← boardnext 2026-08next 2026-10next 2027-04next 2027-10
MIRM
Mirum Pharmaceuticals, Inc.distress 2/10 · well-funded / low risk$111.92-2%today-13% from 52w high
Lead: Chronic Hepatitis D Infection · est. market ~$10B (approx, global)
Revenue
$160M
Liquidity
$421M
Runway
2.5 yrs
Shares 1y
+21%
Price & events
+16.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.2%
1D
-4.6%
1W
+0.8%
1M
+21.7%
3M
+18.7%
6M
+111.0%
1Y
+178.4%
2Y
+613.8%
5Y
+516.7%
All
Overview
- Market Cap
- $6.83B
- Volume
- 57.42K
- 52 Week Range
- $51.12 – $129
- Total Shares
- 60.98M
- Float Shares
- 52.46M
- Short %
- 16.10%
- % Held by Insiders
- 1.39%
- % Held by Institutions
- 114.41%
- RVOL
- 0.06x
- Beta
- 0.48
Pipeline stages · 4 programs
Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Maralixibat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Volixibat
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 7 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mgbreakthrough | Chronic Hepatitis D Infection | — | active not recruiting |
| 2026-10 Estimated 50% readout ~2026-12-15 | Phase 3 | Maralixibat | Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | — | active not recruiting |
| 2027-04 Estimated 50% readout ~2027-05-16 | Phase 2 | Volixibat | Primary Biliary Cholangitis, PBC | — | recruiting |
| 2027-06-30 Estimated 50% readout ~2027-09-13 | Phase 3 | Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mgbreakthrough | Chronic Hepatitis D Infection | — | recruiting |
| 2027-08-31 Estimated 50% readout ~2027-11-14 | Phase 2/3 | Brelovitug (BJT-778), Bulevirtidebreakthrough | Chronic Hepatitis D | — | recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379 | Fragile X Syndrome | — | recruiting |
| 2029-05 Estimated 50% readout ~2029-07-15 | Phase 2/3 | Brelovitug 300 mg, Brelovitug 900 mg, Delayed Treatment with Brelovitug 300mgbreakthrough | Chronic Hepatitis D Infection | — | active not recruiting |
| 2026-06 | Phase 2 | Volixibat | Primary Sclerosing Cholangitis | 182 | active not recruiting |
| 2025-04-23 | Phase 3 | Maralixibat | Progressive Familial Intrahepatic Cholestasis (PFIC) | 84 | completed |
Catalyst news & presentations · 11
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)brelovitug · Potential BLA submissionSEC 8-K
- first quarter of 2027Guided 70%readoutPhase 2volixibat · Topline data from VANTAGE Phase 2b study of volixibat in PBCSEC 8-K
- second half of 2026Guided 55%readoutPhase 3brelovitug · Topline Phase 3 results from AZURE programSEC 8-K
- second half of 2026Guided 55%regulatory submissionFiled (NDA/BLA)volixibat · Planned NDA submission for volixibat in PSCSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- May 30, 2026 at 2:15 p.m. CESTconferencedata presentationsecondaryPhase 2volixibat · Late-breaking oral presentation of VISTAS Phase 2b results at EASL International Liver CongressSEC 8-K
- May 27-30, 2026conferencedata presentationsecondarybrelovitug · Late-breaking poster presentation at EASL CongressSEC 8-K
- 2026-01-23partnershipConcurrent private placement raising $268.5MSEC 8-K
- 2026-01-23partnershipAcquisition of Bluejay Therapeutics completedSEC 8-K
- 2025-12-19fda agreementLivmarli · Filed patent infringement suits against ANDA filers, resulting in 30-month stay on FDA approval of genericsSEC 8-K
- 2025-12-06partnershipAgreement to acquire Bluejay Therapeutics via merger with upfront cash and stock consideration.SEC 8-K
Approved drugs (4)
- LIVMARLIMARALIXIBAT CHLORIDE2025 · Prescription
- CTEXLICHENODIOL2025 · Prescription
- LIVMARLIMARALIXIBAT CHLORIDE2021 · Prescription
- CHOLBAMCHOLIC ACID2015 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $147 (+31% upside) · 14 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-07-02JP MorganOverweight
- 2026-06-15CitizensMarket Outperform
- 2026-06-11Morgan StanleyOverweight
- 2026-06-02CitigroupBuy
- 2026-05-19Wolfe ResearchOutperform
Competitors — Chronic Hepatitis D Infection
- none identified
Recent news
- 2026-07-20Why (MIRM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
- 2026-07-13Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2026-07-13Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2026-07-09Insider Sell Alert: Eric Bjerkholt Sells 5,000 Shares of Mirum P - GuruFocus
- 2026-07-08Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Canada
- 2026-07-08Mirum Pharmaceuticals (MIRM) CFO sells 5,000 shares under 10b5-1 plan - Stock Titan
- 2026-07-08Mirum Pharmaceuticals CEO Christopher Peetz sells $2.4 million in stock - Investing.com
- 2026-07-08Mirum Pharmaceuticals CFO Eric Bjerkhot sells $611,273 in stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.